[Skin cancer: what's new in clinical research?].
Every year skin cancer is the subject of many publications. In this review of the recent literature, we selected epidemiological, clinical, and therapeutic data published between October 2006 and September 2007. Some of the studies presented in conferences in 2007 are also mentioned. New epidemiological data have been provided regarding the incidence of different types of skin cancers, the effect of certain risk factors or drug or food protective factors, the overall improvement of survival in melanoma, the epidemiological, clinical, and/or therapeutic particularities of rapidely growing melanomas and thick melanomas, and the relations between sun exposure, skin cancers, and other solid tumors. New prognostic studies in melanoma have improved the evaluation of prognosis in specific situations such as thin melanoma, acrolentiginous melanoma, and melanoma with positive sentinel lymph nodes (depending on the type of positivity) or negative sentinel lymph nodes. Important results on adjuvant interferon in melanoma have been presented. Clinical trials evaluating new therapeutic approaches in stage III and IV melanoma are going on. Several studies confirmed the clinical benefit of adjuvant irradiation on the tumor site in Merkel cell carcinoma. New treatments are being studied or have been approved in refractory forms of cutaneous T-cell lymphoma and in inoperable forms of squamous cell carcinoma and dermatofibrosarcoma protuberans.
Grange
F
F
Service de Dermatologie, Hôpital Robert-Debré, avenue du Général-Koenig, 51092 Reims cedex, France. fgrange@chu-reims.fr
D000970:Antineoplastic Agents / Q000627:therapeutic use; D035843:Biomedical Research / Q000639:trends*; D002277:Carcinoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D015266:Carcinoma, Merkel Cell / Q000628:therapy; D018223:Dermatofibrosarcoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D019317:Evidence-Based Medicine; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007372:Interferons / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000453:epidemiology / Q000628:therapy*; D008545:Melanoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D012878:Skin Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D007372:Interferons